Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non Operating Income: 2016-2024

Historic Non Operating Income for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Dec 2024 value amounting to $5.2 million.

  • Rhythm Pharmaceuticals' Non Operating Income fell 74.82% to $274,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year decrease of 131.93%. This contributed to the annual value of $5.2 million for FY2024, which is 2059.26% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Non Operating Income of $5.2 million as of FY2024, which was up 2,059.26% from $243,000 recorded in FY2023.
  • Rhythm Pharmaceuticals' Non Operating Income's 5-year high stood at $100.4 million during FY2021, with a 5-year trough of -$2.0 million in FY2022.
  • For the 3-year period, Rhythm Pharmaceuticals' Non Operating Income averaged around $1.2 million, with its median value being $243,000 (2023).
  • In the last 5 years, Rhythm Pharmaceuticals' Non Operating Income slumped by 101.95% in 2022 and then soared by 2,059.26% in 2024.
  • Over the past 4 years, Rhythm Pharmaceuticals' Non Operating Income (Yearly) stood at $100.4 million in 2021, then tumbled by 101.95% to -$2.0 million in 2022, then skyrocketed by 112.39% to $243,000 in 2023, then surged by 2,059.26% to $5.2 million in 2024.